Erik Lundgren

Publications

Author

Title

Year sorteringsordning

Fulltext

Suhr, Ole B.
Lundgren, Erik
Westermark, P

One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition
Journal of Internal Medicine, 281(4): 337-347

2017

-

Andersson, Karin
Pokrzywa, M
Dacklin, Ingrid; et al.

Inhibition of TTR aggregation-induced cell death: a new role for serum amyloid P component
PLoS ONE, 8(2)

2013

Download

Blomberg, Jeanette
Höglund, Andreas
Eriksson, David; et al.

Inhibition of cellular FLICE-like inhibitory protein abolishes insensitivity to interferon-α in a resistant variant of the human U937 cell line
Apoptosis (London), 16(8): 783-794

2011

-

Noborn, Fredrik
O'Callaghan, Paul
Hermansson, Erik; et al.

Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein
Proceedings of the National Academy of Sciences of the United States of America, 108(14): 5584-5589

2011

-

Pokrzywa, Malgorzata
Dacklin, Ingrid
Vestling, Monika; et al.

Uptake of aggregating transthyretin by fat body in a drosophila model for TTR-associated amyloidosis
PloS one, 5(12): e14343-

2010

-

Suhr, Ole B
Lundgren, Erik
Westermark, Per

Transthyretin amyloidoses: new strategies for therapeutic intervention
Drugs of the future, 35(4): 325-332

2010

-

Blomberg, Jeanette
Ruuth, Kristina
Jacobsson, Maria; et al.

Reduced FAS transcription in clones of U937 cells that have acquired resistance to Fas-induced apoptosis
The FEBS Journal, 276(2): 497-508

2009

-

Sundström, Peter
Nyström, Maria
Ruuth, Kristina; et al.

Antibodies to specific EBNA-1 domains and HLA DRB1*1501 interact as risk factors for multiple sclerosis.
Journal of Neuroimmunology, 215(1-2): 102-107

2009

-

Ericzon, Bo-Göran
Lundgren, Erik
Suhr, Ole B.

Liver Transplantation for Transthyretin Amyloidosis

2009

-

Strannegård, Orian
Thorén, Fredrik B
Lundgren, Erik

[Interferon-alpha can improve the prognosis in high-risk melanoma. Combination of surgery, cytostatics and natural IFN-alpha doubled the survival rate.]
Läkartidningen, 105(6): 358-361

2008

-


Page Editor: Selma Grönlund

Print page